In vitro, it upregulates osteoblast markers like ALP [73], stimulates bone formation by increasing OPN (Osteopontin) and BSP production, and inhibits osteoclast differentiation by increasing OPG (Osteoprotegerin) production, having implications for osteoporosis treatment [73]. Here, TNFRSF11B is linked to osteoporosis.